FDA Deems Angiomax sNDA "Not Approvable"

Bivalirudin supplemental application for patients undergoing percutaneous coronary intervention contained deficiencies in both the study methods and the analysis, FDA finds. Drug sponsor The Medicines Company plans to request a meeting with the agency.